(313 days)
Not Found
No
The summary describes a synthetic bone graft substitute material and its physical properties and performance in animal and bench tests. There is no mention of any software, algorithms, or data processing that would indicate the use of AI or ML.
Yes
The device is described as an implant intended to fill bony voids or gaps of the skeletal system, which resorbs and is replaced with bone during the healing process, indicating a therapeutic function of aiding in bone repair and regeneration.
No
Explanation: The device is a bone graft substitute intended to fill bony voids, not to diagnose medical conditions.
No
The device description clearly states that NuROs Bone Graft Substitute is a physical implant made of synthetic beta-tricalcium phosphate (B-TCP) in granule and block forms. It is a tangible material intended to fill bony voids.
Based on the provided information, the NuROs Bone Graft Substitute is not an IVD (In Vitro Diagnostic) device.
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens taken from the human body (like blood, urine, or tissue) to provide information for diagnosis, monitoring, or screening.
- NuROs Bone Graft Substitute's Function: The description clearly states that NuROs Bone Graft Substitute is an implant intended to fill bony voids or gaps within the skeletal system. It is surgically placed within the body and resorbs over time, being replaced by bone.
- No Specimen Testing: There is no mention of this device being used to test or analyze any specimens taken from the body. Its function is entirely within the body as a structural support and scaffold for bone regeneration.
Therefore, based on its intended use and description, NuROs Bone Graft Substitute falls under the category of a surgical implant or bone graft substitute, not an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
NuROs Bone Graft Substitute is an implant intended to fill bony voids or gaps of the skeletal system, i.e., extremities and pelvis. These osseous defects are surgically created or the result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure. NuROs Bone Graft Substitute resorbs and is replaced with bone during the healing process.
Product codes (comma separated list FDA assigned to the subject device)
MQV
Device Description
NuROs Bone Graft Substitute is an osteoconductive bone void filler with interconnective pore system. It is made of synthetic beta-tricalcium phosphate (B-TCP) indicated for bone void filling. It is suitable for individuals with bone voids of gaps, caused by surgery or trauma.
NuROs Bone Graft Substitute is available in granule type and block type with different volumes which are 1c.c, 2.5c.c, 5c.c, 10c.c, 20c.c, 25c.c and 30c.c. Granule types are provided in 0.2 ~ 0.5mm, 0.5 ~ 1mm, 1 ~ 2mm and 3mm of particle size. Block type is provided in 5mm x 5mm x 10mm, 5mm x 20mm, 10mm x 10mm x 10mm and 10mm x 25mm x 25mm size.
NuROs Bone Graft Substitute is pure ß-TCP with all crystalline phase. The Ca/P ratio is 1.5. The structure of the material is multidirectional interconnective porosity with >70% porosity. The propose device does not impart mechanical strength to surgical site.
The NuROs Bone Graft Substitute is gamma irradiated and provided for single use only.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
skeletal system, i.e., extremities and pelvis
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-clinical Testing
- Biocompatibility: According to ISO 10993 > and to the type of medical device (long-term implantable medical device, bone/tissue contact) the following biologic effects have been investigated: Cytotoxicity, Sensitization, Intracutaneous Irritation reactivity, System Toxicity (Acute), Subchronic Toxicity (Subacute Toxicity), Genotoxicity, Implantation, Pyrogenicity. Testing performed on NuROs shows biocompatible with no significant adverse observations of any kind.
- Bench test: A series of bench tests were conducted on the proposed device, NuROs Bone Graft Substitute. Testing included: Chemical Composition, Elemental Analysis, Structure Observation, Specification of Device Porosity, TGA-residue Analysis, Ultra Trace Elements, pH Test, Pore Size Distribution. The results showed that the proposed device have the same characteristics as the predicate device.
- Animal Test: The animal test was conducted to observe the difference in degradation rate, bone-defect interface and the state of overall healing in the animal between proposed device and predicate device. The bone grafts were implanted into porcine models and tracked for a period of time. Each tibia of the pig was drilled with two blind-ended tunnels and different bone grafts were implanted into each tunnel of each leg. CT Scans, X-rays and Histomorphometry were taken in order to observe and assess the results. The diameters of the defects were measured and recorded at each point in time to illustrate the degradation rate of the implant and healing rate of the bone defect. After the 1st and the 3rd month, the data showed that the proposed device, NuROs Bone Graft Substitute is as effective as the predicate device.
Clinical Testing
No clinical test data was used to support the decision of safety and effectiveness.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 888.3045 Resorbable calcium salt bone void filler device.
(a)
Identification. A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.(b)
Classification. Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.
0
Image /page/0/Picture/1 description: The image shows the seal of the U.S. Department of Health and Human Services. The seal features a stylized caduceus, a symbol often associated with medicine and healthcare, with three intertwined snakes and a staff. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the caduceus.
February 17, 2015
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
Oriental Resources Development Limited % Mr. Michael Lee AcmeBiotechs Company, Limited No. 45 Minsheng Road, Danshui Town New Taipei City, Taiwan 251 Republic of China
Re: K140913
Trade/Device Name: NuROs Bone Graft Substitute Regulation Number: 21 CFR 888.3045 Regulation Name: Resorbable calcium salt bone void filler device Regulatory Class: Class II Product Code: MQV Dated: December 31, 2014 Received: January 8, 2015
Dear Mr. Lee:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing
1
Page 2 - Mr. Michael Lee
(21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Mark N. Melkerson -S
Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
NuROs Bone Graft Substitute 510(k) Number: K140913/S002
Indications for Use
510(k) Number (if known): K140913
NuROs Bone Graft Substitute Device Name:
Indications for Use:
NuROs Bone Graft Substitute is an implant intended to fill bony voids or gaps of the skeletal system, i.e., extremities and pelvis. These osseous defects are surgically created or the result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure. NuROs Bone Graft Substitute resorbs and is replaced with bone during the healing process.
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
CONCURRENCE of CDRH, Office of Device Evaluation (ODE)
Page 1 of
3
NuROs Bone Graft Substitute 510(k) Number: K140913/S002
Section 5
510(k) Summary
4
NuROs Bone Graft Substitute 510(k) Number: K140913/S002
510(k) Summary
| 5.1 | Type of Submission: | Traditional |
|---|---|---|
| 5.2 | Preparation Date: | 25th March 2014 |
| 5.3 | Submitter: | Oriental Resources Development Limited |
| Address: | 2F., No.30, Hexing Rd., Hukou Township, | |
| Hsinchu County 303, Taiwan (R.O.C.) | ||
| Phone: | +886-3-5997135 Ext. 843 | |
| Fax: | +886-3-6208066 | |
| Contact: | Wei-Chun Chang (raychang@feg.com.tw) | |
| Registration number: | 3010275504 |
5.4 Identification of the Device:
| Proprietary/
| Trade name: | NuROs Bone Graft Substitute |
|---|---|
| Classification Name: | Resorbable calcium salt bone void filler device |
| Device Classification: | II |
| Regulation Number: | 888.3045 |
| Panel: | Orthopedic |
| Product Code: | MQV |
5.5 Identification of the Predicate Device:
| Predicate Device Name: | BIOSORB® Resorbable Bone Void Filler |
|---|---|
| Manufacturer: | Sciences et Bio Matériaux |
| Product Code: | MQV |
| 510(k) Number: | K021963 |
5
5.5 Intended Use and Indications for Use of the subject device.
NuROs Bone Graft Substitute is an implant intended to fill bony voids or gaps of the skeletal system, i.e., extremities and pelvis. These osseous defects are surgically created or the result of traumatic injury to the bone and are not intrinsic to the stability of the bony structure. NuROs Bone Graft Substitute resorbs and is replaced with bone during the healing process.
5.6 Device Description
NuROs Bone Graft Substitute is an osteoconductive bone void filler with interconnective pore system. It is made of synthetic beta-tricalcium phosphate (B-TCP) indicated for bone void filling. It is suitable for individuals with bone voids of gaps, caused by surgery or trauma.
NuROs Bone Graft Substitute is available in granule type and block type with different volumes which are 1c.c, 2.5c.c, 5c.c, 10c.c, 20c.c, 25c.c and 30c.c. Granule types are provided in 0.2 ~ 0.5mm, 0.5 ~ 1mm, 1 ~ 2mm and 3mm of particle size. Block type is provided in 5mm x 5mm x 10mm, 5mm x 20mm, 10mm x 10mm x 10mm and 10mm x 25mm x 25mm size.
NuROs Bone Graft Substitute is pure ß-TCP with all crystalline phase. The Ca/P ratio is 1.5. The structure of the material is multidirectional interconnective porosity with >70% porosity. The propose device does not impart mechanical strength to surgical site.
The NuROs Bone Graft Substitute is gamma irradiated and provided for single use only.
6
NuROs Bone Graft Substitute 510(k) Number: K140913/S002
5.7 Non-clinical Testing
5.7.1 Biocompatibility
According to ISO 10993 > and to the type of medical device (long-term implantable medical device, bone/tissue contact) the following biologic effects have been investigated:
- A Cytotoxicity
- A Sensitization
-
Intracutaneous Irritation reactivity
- System Toxicity (Acute) >
-
Subchronic Toxicity (Subacute Toxicity)
-
Genotoxicity
- A Implantation
-
Pyrogenicity
Testing performed on NuROs shows biocompatible with no significant adverse observations of any kind.
5.7.2 Bench test
A series of bench tests were conducted on the proposed device, NuROs Bone Graft Substitute.
- A Chemical Composition
-
Elemental Analysis
- A Structure Observation
-
Specification of Device Porosity
-
TGA-residue Analysis
-
Ultra Trace Elements
- A pH Test
-
Pore Size Distribution
The results showed that the proposed device have the same characteristics as the predicate device.
5.7.3 Animal Test
The animal test was conducted to observe the difference in degradation rate, bone-defect interface and the state of overall healing in the animal between
7
proposed device and predicate device. The bone grafts were implanted into porcine models and tracked for a period of time. Each tibia of the pig was drilled with two blind-ended tunnels and different bone grafts were implanted into each tunnel of each leg. CT Scans, X-rays and Histomorphometry were taken in order to observe and assess the results. The diameters of the defects were measured and recorded at each point in time to illustrate the degradation rate of the implant and healing rate of the bone defect. After the 1st and the 3rd month, the data showed that the proposed device, NuROs Bone Graft Substitute is as effective as the predicate device.
A series of safety tests were performed to assess the safety and effectiveness of the NuROs Bone Graft Substitute.
| Testing Item | Standard and regulations applied |
|---|---|
| Biocompatibility | ISO 10993-1 Biological evaluation of medical devices -- Part I : Evaluation and testing. |
| ISO 10993-3 Biological evaluation of medical devices -- Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity | |
| ISO 10993-5 Biological evaluation of medical devices -- Part 5: Tests for in vitro cytotoxicity | |
| ISO 10993-6 Biological evaluation of medical devices -- Part 6: Tests for local effects after implantation | |
| ISO 10993-10 Biological evaluation of medical devices -- Part 10: Tests for irritation and skin sensitization | |
| ISO 10993-11 Biological evaluation of medical devices -- Part 11: Tests for systemic toxicity | |
| ISO 10993-12 Biological evaluation of medical devices -- Part 12: Sample preparation and reference material | |
| Sterilization and | |
| shelf life | ISO 11737-1:2006 Sterilization of medical devices - Microbiological methods - Part 1: Determination of a population of microorganisms on products |
| ISO 11737-2:2009 Sterilization of medical devices - Microbiological methods – Part 2: Tests of sterility performed in the definition, validation and maintenance of a sterilization |
8
NuROs Bone Graft Substitute 510(k) Number: K140913/S002
| process | |
|---|---|
| ISO 11137-2:2009 Sterilization of health care products – | |
| Radiation – Part 2: Establishing the sterilization dose | |
| ASTM F1980-07 Standard Guide for Accelerated Aging of Sterile | |
| Barrier Systems for Medical Devices | |
| ASTM F88-85 Standard Test Method for Seal Strength of Flexible | |
| Barrier Materials | |
| ASTM F1140:2000 Standard Test Methods for Internal | |
| Pressurization Failure Resistance of Unrestrained Packages for | |
| Medical Applications. | |
| ASTM D4332: 2001 Standard practice conditioning containers, | |
| packages or packaging components for testing | |
| ASTM 1608 Standard Test Method for Microbial Ranking of | |
| Porous Packaging Materials (Exposure Chamber Method) | |
| ASTM F1929-98 Standard test Method for Detecting Seal Leaks | |
| in Porous Medical Packaging by Dye Penetration | |
| Performance | ASTM F1088-04a Standard Specification for Beta-Tricalcium |
| Phosphate for Sugical Implantation |
NuROs Bone Graft Substitute conforms to the recognized consensus standard specification for surgically implantable beta-tricalcium phosphate. The biocompatibility of beta-TCP implants is also well documented. As a biomaterial, beta-TCP has consistently proven to be non-toxic, non-allergenic, and biocompatible and elicits no inflammation. No adverse system effects have been observed.
All the test results demonstrate NuROs Bone Graft Substitute meets the requirements of its pre-defined acceptance criteria and intended uses.
5.8 Clinical Testing
No clinical test data was used to support the decision of safety and effectiveness.
9
NuROs Bone Graft Substitute 510(k) Number: K140913/S002
5.9 EMC and Electrical safety
The devices do not require EMC/Electrical Safety evaluation.
5.10 Substantial Equivalence Determination
The NuROs Bone Graft Substitute has similar intended use, fundamental scientific technology, and technological characteristics with the predicate device. Information described below can demonstrate the NuROs Bone Graft Substitute is substantial equivalent to the predicate device.
| Item | Predicate Device | Subject Device |
|---|---|---|
| Trade name | BIOSORB® Resorbable Void Filler | NuROs Bone Graft Substitute |
| K number | K021963 | |
| Regulation no./ Class | 888.3045 / II | 888.3045 / II |
| Classification name | Resorbable calcium salt bone void | |
| filler device | Resorbable calcium salt bone | |
| void filler device | ||
| Product code/ | ||
| Device panel | MQV / Orthopedic | MQV / Orthopedic |
| Intended use | BIOSORB® Resorbable Void Filler | |
| is a resorbable calcium salt bone void | ||
| filler intended to fill bony voids or | ||
| gaps of the skeletal system (i.e. the | ||
| extremities, spine and pelvis,) caused | ||
| by trauma or surgery, that are not | ||
| intrinsic to the stability of the bony | ||
| structure. | ||
| BIOSORB® Resorbable Void Filler | ||
| does not possess sufficient | ||
| mechanical strength to support | ||
| reduction of a defect prior to soft and | ||
| hard tissue ingrowth. Rigid fixation | ||
| techniques are recommended as | ||
| needed to assure stabilization of the | ||
| defect in all plans. | NuROs Bone Graft Substitute is | |
| an implant intended to fill bony | ||
| voids or gaps of the skeletal | ||
| system, i.e., extremities and | ||
| pelvis. These osseous defects are | ||
| surgically created or the result of | ||
| traumatic injury to the bone and | ||
| are not intrinsic to the stability | ||
| of the bony structure. NuROs | ||
| Bone Graft Substitute resorbs | ||
| and is replaced with bone during | ||
| the healing process. |
10
NuROs Bone Graft Substitute 510(k) Number: K140913/S002
| Biocompatibility | Established | Established | |
|---|---|---|---|
| Sterility | Sterilize (gamma radiation) | ||
| Single use only | Same as predicate | ||
| Similarity | |||
| Structure | multidirectional interconnected | ||
| porosity structure | Same as predicate device | ||
| Chemical composition | β-Tricalciumphosphate | ||
| (Ca3(PO4)2) | Same as predicate device | ||
| Mechanical Strength | Does not impart mechanical | ||
| strength to surgical site | Same as predicate device | ||
| Porosity of material | 70% | 70% | |
| Ca/P ratio | 1.5 | 1.5 | |
| Pore size | 30 ~400 μm | 70 ~400 μm | |
| Differences | |||
| Shape and | |||
| Size | Granule type | vary in particle size | |
| (0.6mm to 3mm) | • 0.2 ~ 0.5mm | ||
| • 0.5 ~ 1mm | |||
| • 1 ~ 2mm | |||
| • 3mm | |||
| Block type | |||
| (LxHxW mm) | 10 x 10 x 25 | ||
| 15 x10 x 4 | |||
| 30 x 20 x10 | 5 x 5 x 10 | ||
| 5 x 5 x 20 | |||
| 10 x 10 x 10 | |||
| 10 x 25 x 25 | |||
| Cube type | vary in particle size | ||
| ( 5mm to 10mm) | - | ||
| Macroporous | |||
| cubes | 4mm x 4mm x 4mm | - | |
| Stick type | 5mm x 5mm x 10mm, | ||
| 5mm x 5mm x 20mm | - | ||
| Cylinder type | 6mm to 8mm | - |
11
5.11 Similarity and differences
There were some differences between the proposed device and predicate device. The proposed device was designed in two type of shape (granule and block) with different particle size, predicate device was designed in six types (granule, block, cube, macroporous cube, stick and cylinder).
A series of bench tests were performed which included the chemical composition, elemental analysis, structure observation, specification of device porosity, TGA-residue analysis, ultra trace elements testing and pH testing. The results showed that same as the predicate device, the proposed device was composed of pure beta-TCP and all crystalline phase, no other impurities were presented, the ratio of Ca to P was approximately 1.5, has similar porous structures, no unsintered material or any trace elements and the ultra-trace elements concentrations were in accordance with the standard. The animal test data also showed that the proposed device, NuROs Bone Graft Substitute is as effective as the predicate device.
The proposed device has tested on safety and performance tests and the test results were complied with the test requests. Therefore, the differences of proposed device and predicate device didn't raise any problems of safety or effectiveness. The proposed device is substantially equivalent to the predicate device in design, operation, intended use and performance claims.
5.12 Conclusion
After analyzing bench and animal tests, device description and intended use/indications for use, it can be concluded that NuROs Bone Graft Substitute is as safe and effective as the predicate device.